GlassScriptPhysician profile
Charles W Bryan
NPI 1831189877
$1,794.50
in general payments reported to CMS, 2019-2025
30 companies · $352 in 2025
The $352 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $433 · 2023: $199 · 2024: $682 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195 · Education: $39.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.79 |
| Education | $39.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $328.72 | 2021-2024 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $317.45 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $150.00 | 2024 | |
| Pfizer INC. | $142.69 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $88.85 | 2024-2025 | Welireg, Keytruda, Keytruda Qlex |
| Amgen INC. | $82.87 | 2022-2023 | Lumakras, Kyprolis |
| Celgene Corporation | $74.56 | 2023-2024 | Pomalyst |
| Beigene USA, INC. | $67.66 | 2022-2023 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $48.56 | 2024-2025 | Lynparza, Enhertu |
| Abbvie INC. | $44.82 | 2021-2025 | |
| Gilead Sciences, INC. | $43.53 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $31.11 | 2023-2025 | Opdivo |
| Exelixis INC. | $29.62 | 2025 | Cabometyx |
| Astellas Pharma US INC | $28.35 | 2024 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $27.32 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $23.78 | 2025 | Lorbrena, Braftovi, Mektovi |
| Regeneron Healthcare Solutions, INC. | $23.03 | 2024 | Libtayo |
| Incyte Corporation | $22.60 | 2024 | Jakafi |
| Genmab U.S., INC. | $22.18 | 2024 | Epkinly |
| Servier Pharmaceuticals LLC | $21.70 | 2024 | |
| Morphosys, US INC. | $21.23 | 2021 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Syndax Pharmaceuticals, INC. | $18.92 | 2025 | |
| Puma Biotechnology, INC. | $18.88 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.49 | 2024 | Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $16.98 | 2022 | |
| Daiichi Sankyo INC. | $16.55 | 2025 | Injectafer |
| Coherus Oncology, INC. | $16.47 | 2025 | Loqtorzi |
| Genentech USA, INC. | $15.67 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.